[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,799,403
  • Shares Outstanding, K 446,502
  • Annual Sales, $ 263,500 K
  • Annual Income, $ -390,980 K
  • EBIT $ -319 M
  • EBITDA $ -279 M
  • 60-Month Beta 0.73
  • Price/Sales 6.91
  • Price/Cash Flow N/A
  • Price/Book 2.52

Options Overview Details

View History
  • Implied Volatility 100.12% (+7.15%)
  • Historical Volatility 86.62%
  • IV Percentile 16%
  • IV Rank 4.89%
  • IV High 1,223.10% on 07/21/25
  • IV Low 42.44% on 06/25/25
  • Expected Move (DTE 2) 0.21 (5.56%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 6,207
  • Volume Avg (30-Day) 8,524
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 242,871
  • Open Int (30-Day) 230,334
  • Expected Range 3.61 to 4.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.18
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +48.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.28 +16.46%
on 05/19/26
4.58 -16.55%
on 06/04/26
+0.37 (+10.72%)
since 05/15/26
3-Month
3.18 +20.06%
on 04/07/26
4.58 -16.55%
on 06/04/26
-0.22 (-5.45%)
since 03/16/26
52-Week
1.66 +130.12%
on 06/27/25
5.63 -32.15%
on 03/09/26
+1.74 (+83.65%)
since 06/16/25

Most Recent Stories

More News
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors  Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Q1 Earnings Call Highlights

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL)...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics: Q1 Earnings Snapshot

Iovance Biotherapeutics: Q1 Earnings Snapshot

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Reports Tomorrow With Commercial Launch Momentum Under the Microscope

Barchart Research What to Expect from IOVA Earnings IOVA Generated May 6, 2026 Current Price $4.09 EPS Estimate $$-0.19 Consensus Rating Moderate Buy Average Move 17.92% Iovance Biotherapeutics Reports...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 3.82 (-5.21%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 3.82 (-5.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 4.36
2nd Resistance Point 4.25
1st Resistance Point 4.03
Last Price 3.82
1st Support Level 3.70
2nd Support Level 3.59
3rd Support Level 3.37

See More

52-Week High 5.63
Fibonacci 61.8% 4.11
Last Price 3.82
Fibonacci 50% 3.64
Fibonacci 38.2% 3.18
52-Week Low 1.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.